|
|
|
|
|
|
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.US |
First Approval Date31 Oct 1949 |
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP). Arm 2: Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) (IPT-SPAQ). Arm 3: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence and disease incidence in young children sleeping student's households to assess the impact on transmission.
100 Clinical Results associated with Hemozoin x DNA
100 Translational Medicine associated with Hemozoin x DNA
0 Patents (Medical) associated with Hemozoin x DNA